In what it says is the largest ever global out-licensing agreement by a Chinese biotech, I-Mab Biopharma Co., Ltd has entered into a global partnership with AbbVie Inc. for a CD47 antibody worth close to $2bn in total, including $200m upfront.
$2bn AbbVie Deal Puts I-Mab On Global Immuno-Oncology Map
Safety Of CD47 Asset A Major Attraction?
In another clear signal that China's innovative drug R&D is coming of age, most global rights to I-Mab's promising early-stage CD47 antibody have been picked up by AbbVie in a deal valued at close to $2bn.
